The development of pembrolizumab from the first-in-humans study to FDA approval for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAFV600 mutation positive, a BRAF inhibitor, has occurred in a record 3.6 years. This evidence concerns the gene BRAF and metastatic melanoma.